Fecal Microbiota Transplantation (FMT) is an investigational treatment that offers great promise. FMT involves transplanting carefully screened, processed stool from a healthy donor into a sick patient’s colon. Researchers have observed FMT to be as much as 90% effective for the treatment of recurrent C. difficile, a potentially deadly gastrointestinal infection.
Based on the currently available body of evidence of FMT for recurrent C. difficile, medical professional societies have advocated for FMT as standard of care for patients with this infection. A summary of the results of FMT studies for recurrent C. difficile can be found in Table 1, below. Given this body of evidence and the lack of viable alternative options for patients, the FDA has allowed clinicians to provide FMT to recurrent C. difficile patients outside of clinical trials.
In addition to the available research on FMT for recurrent C. difficile, promising results in ulcerative colitis and other disease areas (summarized in Table 2 below) further support the ongoing investigation of FMT. As the field matures, ongoing research should, and will, continue to explore the safety and efficacy of FMT for C. difficile and other diseases. We look forward to supporting the network of researchers exploring these questions.
Table 1: Summary of FMT studies for recurrent C. difficile infection
Table 2: Summary of FMT studies in disease areas outside recurrent C. difficile